Market attractiveness remains robust, driven by a prevalence of 0.3% globally and rising biologic uptake, delivering a CAGR of 7‑8% through 2032. Competitive intensity is moderate to high; three legacy biologics dominate >60% share, yet a pipeline of five phase‑III candidates promises entry‑level disruption. The long‑term outlook is positive, with expanding indications and aging demographics supporting sustained demand, though price‑erosion pressures could temper growth. Innovation landscape is vibrant: next‑generation IL‑23 inhibitors, oral JAK‑selective agents, and gene‑editing approaches are advancing, suggesting a shift toward more convenient, personalized regimens. Demand–supply balance currently favors suppliers, as manufacturing capacity lags behind projected volume growth, prompting firms to invest in flexible biologics platforms. Key risk factors include reimbursement tightening, regulatory delays for novel modalities, and potential safety signals from long‑term immunomodulation. Overall, the psoriatic arthritis treatment market outlook signals attractive upside for investors who can navigate pricing dynamics and capitalize on emerging therapeutic classes. Stakeholders should monitor biosimilar entry timelines and real‑world effectiveness data, which will shape pricing strategies and formulary placement.
